{"component": "clause", "props": {"groups": [{"samples": [{"hash": "9bYDb0PY8Ij", "uri": "/contracts/9bYDb0PY8Ij#cvrs", "label": "Contingent Value Rights Agreement (Sientra, Inc.)", "score": 28.4442157745, "published": true}, {"hash": "22CFnNLFaLa", "uri": "/contracts/22CFnNLFaLa#cvrs", "label": "Contingent Value Rights Agreement (Daiichi Sankyo Company, LTD)", "score": 25.8213558197, "published": true}, {"hash": "lWFRY7I2yf7", "uri": "/contracts/lWFRY7I2yf7#cvrs", "label": "Contingent Value Rights Agreement (Daiichi Sankyo Company, LTD)", "score": 25.7720737457, "published": true}], "size": 117, "snippet_links": [{"key": "rights-of-holders-to-receive", "type": "clause", "offset": [23, 51]}, {"key": "payments-pursuant-to-this-agreement", "type": "clause", "offset": [68, 103]}, {"key": "initial-holders", "type": "clause", "offset": [109, 124]}, {"key": "terms-of-the-merger-agreement", "type": "clause", "offset": [160, 189]}], "snippet": "The CVRs represent the rights of Holders to receive contingent cash payments pursuant to this Agreement. The initial Holders will be determined pursuant to the terms of the Merger Agreement.", "hash": "441521c4cacad2435c15e7aa55ef720d", "id": 1}, {"samples": [{"hash": "krArwbkmyS", "uri": "/contracts/krArwbkmyS#cvrs", "label": "Contingent Value Rights Agreement (Acelrx Pharmaceuticals Inc)", "score": 31.4065704346, "published": true}, {"hash": "jcCTybPruoG", "uri": "/contracts/jcCTybPruoG#cvrs", "label": "Agreement and Plan of Merger (Acelrx Pharmaceuticals Inc)", "score": 31.4065704346, "published": true}, {"hash": "70PDebVbgdR", "uri": "/contracts/70PDebVbgdR#cvrs", "label": "Agreement and Plan of Merger (Tetraphase Pharmaceuticals Inc)", "score": 31.4065704346, "published": true}], "size": 12, "snippet_links": [{"key": "the-effective-time", "type": "clause", "offset": [53, 71]}, {"key": "right-to-receive", "type": "clause", "offset": [116, 132]}, {"key": "the-merger-consideration", "type": "clause", "offset": [133, 157]}, {"key": "company-warrant", "type": "definition", "offset": [197, 212]}, {"key": "pursuant-to-section", "type": "clause", "offset": [243, 262]}, {"key": "in-accordance-with", "type": "definition", "offset": [311, 329]}, {"key": "initial-holders", "type": "clause", "offset": [345, 360]}, {"key": "terms-of-the-merger-agreement", "type": "clause", "offset": [397, 426]}, {"key": "this-agreement", "type": "clause", "offset": [431, 445]}, {"key": "a-list", "type": "definition", "offset": [451, 457]}, {"key": "to-the-rights-agent", "type": "clause", "offset": [500, 519]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [520, 538]}, {"key": "section-41", "type": "clause", "offset": [565, 576]}], "snippet": "As provided in the Merger Agreement, effective as of the Effective Time, (i) each Share shall be converted into the right to receive the Merger Consideration, which includes one CVR, and (ii) each Company Warrant that is assumed and converted pursuant to Section 5.3(c) of the Merger Agreement shall be treated in accordance with its terms. The initial Holders shall be determined pursuant to the terms of the Merger Agreement and this Agreement, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with Section 4.1 hereof.", "hash": "c103a520e3c8e2b78da212b8164857e8", "id": 2}, {"samples": [{"hash": "6pC8JpomlgU", "uri": "/contracts/6pC8JpomlgU#cvrs", "label": "Contingent Value Rights Agreement (Surface Oncology, Inc.)", "score": 34.6837768555, "published": true}, {"hash": "i1Yn8tL4js5", "uri": "/contracts/i1Yn8tL4js5#cvrs", "label": "Merger Agreement (Coherus BioSciences, Inc.)", "score": 34.4538002014, "published": true}, {"hash": "fbrwWbVyWMB", "uri": "/contracts/fbrwWbVyWMB#cvrs", "label": "Merger Agreement (Surface Oncology, Inc.)", "score": 34.4538002014, "published": true}], "size": 8, "snippet_links": [{"key": "rights-of-the-holders", "type": "clause", "offset": [35, 56]}, {"key": "cvr-payment-amounts", "type": "definition", "offset": [72, 91]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [101, 127]}, {"key": "initial-holders", "type": "clause", "offset": [133, 148]}, {"key": "holders-of-shares", "type": "clause", "offset": [165, 182]}, {"key": "the-effective-time", "type": "clause", "offset": [208, 226]}, {"key": "right-to-receive-merger-consideration", "type": "clause", "offset": [248, 285]}, {"key": "pursuant-to-section", "type": "clause", "offset": [286, 305]}, {"key": "company-equity-awards", "type": "definition", "offset": [360, 381]}, {"key": "section-22", "type": "clause", "offset": [492, 503]}, {"key": "terms-of-the-merger-agreement", "type": "clause", "offset": [585, 614]}, {"key": "a-list", "type": "definition", "offset": [639, 645]}, {"key": "to-the-rights-agent", "type": "clause", "offset": [688, 707]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [708, 726]}, {"key": "in-accordance-with", "type": "definition", "offset": [734, 752]}, {"key": "section-41", "type": "clause", "offset": [753, 764]}], "snippet": "The CVRs represent the contractual rights of the Holders to receive the CVR Payment Amounts, if any, pursuant to this Agreement. The initial Holders will be (a) the holders of Shares that are cancelled as of the Effective Time and converted in the right to receive Merger Consideration pursuant to Section 2.1(a) of the Merger Agreement and (b) the holders of Company Equity Awards that are cancelled as of the Effective Time and converted into the right to receive consideration pursuant to Section 2.2 of the Merger Agreement. The initial Holders shall be determined pursuant to the terms of the Merger Agreement and this Agreement, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with Section 4.1 hereof.", "hash": "38e95498f15d7a45981e3c950daa803b", "id": 3}, {"samples": [{"hash": "1FEiLYkf2CL", "uri": "/contracts/1FEiLYkf2CL#cvrs", "label": "Contingent Value Rights Agreement (Chijet Motor Company, Inc.)", "score": 34.4291572571, "published": true}, {"hash": "3LWfH2ZGJFu", "uri": "/contracts/3LWfH2ZGJFu#cvrs", "label": "Contingent Value Rights Agreement (Chijet Motor Company, Inc.)", "score": 34.1827507019, "published": true}], "size": 5, "snippet_links": [{"key": "rights-of", "type": "definition", "offset": [23, 32]}, {"key": "to-receive", "type": "definition", "offset": [45, 55]}, {"key": "contingent-payment", "type": "clause", "offset": [58, 76]}, {"key": "form-of", "type": "definition", "offset": [84, 91]}, {"key": "pubco-ordinary-shares", "type": "definition", "offset": [92, 113]}, {"key": "pursuant-to-the", "type": "definition", "offset": [190, 205]}, {"key": "this-agreement", "type": "clause", "offset": [214, 228]}], "snippet": "The CVRs represent the rights of CVR Holders to receive a contingent payment in the form of Pubco Ordinary Shares (or in such other form as is provided for herein) and any accrued Earnings, pursuant to the BCA and this Agreement.", "hash": "61fca1b888265ef88b7beaa191bc849c", "id": 4}, {"samples": [{"hash": "ETMuz8SdaR", "uri": "/contracts/ETMuz8SdaR#cvrs", "label": "Contingent Value Rights Agreement (Forest Laboratories Inc)", "score": 22.1800136566, "published": true}, {"hash": "As08d4bvw5", "uri": "/contracts/As08d4bvw5#cvrs", "label": "Contingent Value Rights Agreement (Forest Laboratories Inc)", "score": 22.1498966217, "published": true}], "size": 4, "snippet_links": [{"key": "company-share", "type": "definition", "offset": [50, 63]}, {"key": "company-warrant", "type": "definition", "offset": [95, 110]}, {"key": "company-note", "type": "definition", "offset": [112, 124]}, {"key": "company-dsus", "type": "definition", "offset": [126, 138]}, {"key": "company-option", "type": "definition", "offset": [143, 157]}, {"key": "the-purchaser", "type": "clause", "offset": [167, 180]}, {"key": "for-payment", "type": "clause", "offset": [189, 200]}, {"key": "the-offer", "type": "clause", "offset": [230, 239]}, {"key": "owned-by", "type": "definition", "offset": [250, 258]}, {"key": "issued-to", "type": "definition", "offset": [271, 280]}, {"key": "prior-to-the-effective-time", "type": "clause", "offset": [311, 338]}, {"key": "right-to-receive-merger-consideration", "type": "clause", "offset": [365, 402]}, {"key": "pursuant-to-the-merger-agreement", "type": "clause", "offset": [403, 435]}], "snippet": "Each Holder shall be entitled to one CVR for each Company Share outstanding or underlying each Company Warrant, Company Note, Company DSUs and Company Option (a) that the Purchaser accepts for payment from such Holder pursuant to the Offer or (b) is owned by or has been issued to such Holder as of immediately prior to the Effective Time and is converted into the right to receive merger consideration pursuant to the Merger Agreement.", "hash": "efd30200482c11ddaecd443454d6358b", "id": 5}, {"samples": [{"hash": "jx1sVBM6rg4", "uri": "/contracts/jx1sVBM6rg4#cvrs", "label": "Contingent Value Rights Agreement (Palvella Therapeutics, Inc.)", "score": 35.9568786621, "published": true}, {"hash": "jOMa1V4IOrs", "uri": "/contracts/jOMa1V4IOrs#cvrs", "label": "Contingent Value Rights Agreement (Pieris Pharmaceuticals, Inc.)", "score": 35.5598907471, "published": true}, {"hash": "644jUrRfvhl", "uri": "/contracts/644jUrRfvhl#cvrs", "label": "Contingent Value Rights Agreement (Pieris Pharmaceuticals, Inc.)", "score": 35.5598907471, "published": true}], "size": 3, "snippet_links": [{"key": "company-in", "type": "clause", "offset": [47, 57]}, {"key": "form-of", "type": "definition", "offset": [62, 69]}, {"key": "in-connection-with", "type": "clause", "offset": [82, 100]}, {"key": "the-persons", "type": "clause", "offset": [116, 127]}, {"key": "close-of-business", "type": "definition", "offset": [143, 160]}, {"key": "business-day", "type": "definition", "offset": [173, 185]}, {"key": "the-day", "type": "definition", "offset": [195, 202]}, {"key": "the-effective-time", "type": "clause", "offset": [212, 230]}, {"key": "record-holder-of-shares", "type": "clause", "offset": [245, 268]}, {"key": "public-company-common-stock", "type": "definition", "offset": [272, 299]}, {"key": "company-preferred-stock", "type": "definition", "offset": [320, 343]}, {"key": "to-receive", "type": "definition", "offset": [353, 363]}, {"key": "terms-of", "type": "clause", "offset": [401, 409]}, {"key": "to-the-extent", "type": "clause", "offset": [460, 473]}, {"key": "a-holder-of-a", "type": "clause", "offset": [474, 487]}, {"key": "company-warrant", "type": "definition", "offset": [495, 510]}, {"key": "date-hereof", "type": "clause", "offset": [533, 544]}, {"key": "after-the-closing", "type": "clause", "offset": [624, 641]}, {"key": "a-number", "type": "definition", "offset": [644, 652]}, {"key": "equal-to", "type": "definition", "offset": [661, 669]}, {"key": "number-of-shares-of", "type": "clause", "offset": [674, 693]}, {"key": "issued-to", "type": "definition", "offset": [722, 731]}, {"key": "subject-to-and-in-accordance-with", "type": "clause", "offset": [809, 842]}, {"key": "terms-and-conditions-of", "type": "clause", "offset": [847, 870]}, {"key": "this-agreement", "type": "clause", "offset": [919, 933]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [935, 975]}, {"key": "become-effective", "type": "clause", "offset": [1003, 1019]}, {"key": "void-ab-initio", "type": "definition", "offset": [1073, 1087]}, {"key": "no-effect", "type": "definition", "offset": [1095, 1104]}, {"key": "termination-of-the-merger-agreement", "type": "clause", "offset": [1120, 1155]}], "snippet": "CVRs shall be issued and distributed by Public Company in the form of a dividend, in connection with the Merger, to the Persons who, as of the close of business on the last Business Day prior to the day on which the Effective Time occurs, are a record holder of shares of Public Company Common Stock or shares of Public Company Preferred Stock entitled to receive such dividend in accordance with the terms of such Public Company Preferred Stock. Furthermore, to the extent a holder of a Public Company Warrant outstanding as of the date hereof exercises such Public Company Warrant after the date hereof (whether before or after the Closing), a number of CVRs equal to the number of shares of Public Company Common Stock issued to such holder in connection with such exercise shall be issued to such holder, subject to and in accordance with the terms and conditions of such Public Company Warrant, as applicable, and this Agreement. Notwithstanding anything to the contrary, this Agreement shall only become effective as of, and contingent upon, the Closing and shall be void ab initio and of no effect upon the valid termination of the Merger Agreement.", "hash": "6b293691546a312f5833c04e0c53e1aa", "id": 6}, {"samples": [{"hash": "8vzFEJrDzyj", "uri": "/contracts/8vzFEJrDzyj#cvrs", "label": "Contingent Value Rights Agreement (Concert Pharmaceuticals, Inc.)", "score": 34.1745376587, "published": true}, {"hash": "gCZt6BZ5Z1t", "uri": "/contracts/gCZt6BZ5Z1t#cvrs", "label": "Contingent Value Rights Agreement (Sun Pharmaceutical Industries LTD)", "score": 34.0869255066, "published": true}, {"hash": "kSA8OsTbtNK", "uri": "/contracts/kSA8OsTbtNK#cvrs", "label": "Merger Agreement (Concert Pharmaceuticals, Inc.)", "score": 34.0485954285, "published": true}], "size": 3, "snippet_links": [{"key": "rights-of-holders-to-receive", "type": "clause", "offset": [35, 63]}, {"key": "payments-pursuant-to-this-agreement", "type": "clause", "offset": [80, 115]}, {"key": "in-accordance-with", "type": "definition", "offset": [117, 135]}, {"key": "the-merger-agreement", "type": "clause", "offset": [136, 156]}, {"key": "the-transactions", "type": "clause", "offset": [173, 189]}, {"key": "company-common-stock", "type": "definition", "offset": [252, 272]}, {"key": "covered-equity-award", "type": "definition", "offset": [327, 347]}, {"key": "company-warrant", "type": "definition", "offset": [406, 421]}, {"key": "prior-to-the-effective-time", "type": "clause", "offset": [476, 503]}, {"key": "following-the-effective-time", "type": "clause", "offset": [567, 595]}, {"key": "company-preferred-stock", "type": "definition", "offset": [663, 686]}, {"key": "right-of", "type": "definition", "offset": [712, 720]}, {"key": "a-holder", "type": "definition", "offset": [721, 729]}, {"key": "payments-in", "type": "clause", "offset": [755, 766]}, {"key": "initial-holders", "type": "clause", "offset": [803, 818]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [855, 878]}, {"key": "a-list", "type": "definition", "offset": [884, 890]}, {"key": "to-the-rights-agent", "type": "clause", "offset": [933, 952]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [953, 971]}, {"key": "section-41", "type": "clause", "offset": [998, 1009]}], "snippet": "The CVRs represent the contractual rights of Holders to receive contingent cash payments pursuant to this Agreement. In accordance with the Merger Agreement and pursuant to the Transactions, each Holder is entitled to (a) one CVR for (i) each share of Company Common Stock, (ii) each share of Company Common Stock underlying a Covered Equity Award and (iii) each share of Company Common Stock underlying a Company Warrant that is issued, unexpired and unexercised immediately prior to the Effective Time (\u201cSurviving Warrant\u201d) when such Surviving Warrant is exercised following the Effective Time in accordance with its terms, and (b) 1,000 CVRs for each share of Company Preferred Stock. Each CVR represents the right of a Holder to receive the Milestone Payments in accordance with this Agreement. The initial Holders shall be determined pursuant to the terms of this Agreement, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with Section 4.1.", "hash": "4567d26cc644ce7493a51f4322e09c66", "id": 7}, {"samples": [{"hash": "hlphnie7Lpq", "uri": "/contracts/hlphnie7Lpq#cvrs", "label": "Contingent Value Rights Agreement (Day One Biopharmaceuticals, Inc.)", "score": 37.0136909485, "published": true}, {"hash": "dnmEXZLdfOJ", "uri": "/contracts/dnmEXZLdfOJ#cvrs", "label": "Contingent Value Rights Agreement (Mersana Therapeutics, Inc.)", "score": 37.0136909485, "published": true}, {"hash": "kdiB7Unp5kM", "uri": "/contracts/kdiB7Unp5kM#cvrs", "label": "Contingent Value Rights Agreement (Mersana Therapeutics, Inc.)", "score": 36.8658447266, "published": true}], "size": 3, "snippet_links": [{"key": "offer-acceptance-time", "type": "definition", "offset": [61, 82]}, {"key": "merger-sub", "type": "definition", "offset": [84, 94]}, {"key": "for-payment", "type": "clause", "offset": [107, 118]}, {"key": "pay-for", "type": "definition", "offset": [143, 150]}, {"key": "prior-to-the-effective-time", "type": "clause", "offset": [334, 361]}, {"key": "cancelled-shares", "type": "definition", "offset": [374, 390]}, {"key": "dissenting-company-shares", "type": "definition", "offset": [410, 435]}, {"key": "right-to-receive", "type": "clause", "offset": [465, 481]}, {"key": "the-merger-consideration", "type": "clause", "offset": [482, 506]}, {"key": "fully-vested", "type": "clause", "offset": [545, 557]}, {"key": "exercise-price-payable", "type": "clause", "offset": [648, 670]}, {"key": "company-common-stock", "type": "definition", "offset": [684, 704]}, {"key": "subject-to", "type": "definition", "offset": [705, 715]}, {"key": "company-rsu-award", "type": "definition", "offset": [751, 768]}, {"key": "in-respect-of", "type": "definition", "offset": [939, 952]}, {"key": "initial-holders", "type": "clause", "offset": [1067, 1082]}, {"key": "terms-of-the-merger-agreement", "type": "clause", "offset": [1119, 1148]}, {"key": "this-agreement", "type": "clause", "offset": [1153, 1167]}, {"key": "a-list", "type": "definition", "offset": [1173, 1179]}, {"key": "to-the-rights-agent", "type": "clause", "offset": [1222, 1241]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [1242, 1260]}, {"key": "in-accordance-with", "type": "definition", "offset": [1268, 1286]}, {"key": "section-41", "type": "clause", "offset": [1287, 1298]}], "snippet": "As provided in the Merger Agreement: (i) effective as of the Offer Acceptance Time, Merger Sub will accept for payment and promptly thereafter pay for each Company Share validly tendered and not validly withdrawn pursuant to the Offer; and (ii) effective as of the Effective Time, (A) each Company Share outstanding as of immediately prior to the Effective Time (other than Cancelled Shares and other than any Dissenting Company Shares) shall be converted into the right to receive the Merger Consideration, (B) each Cash-Out Option will become fully vested and cancelled and converted into the right to receive the Merger Consideration (minus the exercise price payable per share of Company Common Stock subject to such Cash-Out Option) and (C) each Company RSU Award outstanding as of immediately prior to the Effective Time (whether vested or unvested) will be cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such Company RSU Award immediately prior to the Effective Time. The initial Holders shall be determined pursuant to the terms of the Merger Agreement and this Agreement, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with Section 4.1.", "hash": "bd80f1d043055239ee5a6afc910e09c4", "id": 8}, {"samples": [{"hash": "ex0QebhzkHe", "uri": "/contracts/ex0QebhzkHe#cvrs", "label": "Contingent Value Rights Agreement", "score": 31.3408622742, "published": true}, {"hash": "cnSQX1AKERW", "uri": "/contracts/cnSQX1AKERW#cvrs", "label": "Agreement and Plan of Merger (UNITED THERAPEUTICS Corp)", "score": 29.3285427094, "published": true}, {"hash": "fWufkBK98ls", "uri": "/contracts/fWufkBK98ls#cvrs", "label": "Contingent Value Rights Agreement (SteadyMed Ltd.)", "score": 29.3258037567, "published": true}], "size": 3, "snippet_links": [{"key": "rights-of-holders", "type": "clause", "offset": [23, 40]}, {"key": "granted-to", "type": "definition", "offset": [42, 52]}, {"key": "initial-holders", "type": "clause", "offset": [57, 72]}, {"key": "pursuant-to-the-merger-agreement", "type": "clause", "offset": [73, 105]}, {"key": "contingent-cash-payment", "type": "definition", "offset": [120, 143]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [144, 170]}, {"key": "excluded-share", "type": "definition", "offset": [322, 336]}, {"key": "issued-and-outstanding", "type": "clause", "offset": [375, 397]}, {"key": "prior-to-the-effective-time", "type": "clause", "offset": [410, 437]}, {"key": "right-to-receive", "type": "clause", "offset": [502, 518]}, {"key": "the-merger-consideration", "type": "clause", "offset": [519, 543]}, {"key": "in-the-money-option", "type": "clause", "offset": [608, 627]}, {"key": "pursuant-to-section", "type": "clause", "offset": [763, 782]}, {"key": "restricted-share-unit", "type": "definition", "offset": [852, 873]}], "snippet": "The CVRs represent the rights of Holders (granted to the initial Holders pursuant to the Merger Agreement) to receive a contingent cash payment pursuant to this Agreement. As provided in the Merger Agreement, each Holder shall be entitled to one CVR for (i) each Share (as defined in the Merger Agreement) (other than any Excluded Share (as defined in the Merger Agreement)) issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) that is converted into the right to receive the Merger Consideration pursuant to the Merger Agreement, (ii) each Share underlying an In the Money Option that is outstanding and unexercised immediately prior to the Effective Time that is converted into the right to receive a cash payment pursuant to Section 2.2(a)(i) of the Merger Agreement; and (iii) each Share underlying a Restricted Share Unit that is outstanding immediately prior to the Effective Time that is converted into the right to receive a cash payment pursuant to Section 2.2(a)(iv) of the Merger Agreement.", "hash": "a339b1b8c9502c3a7eeb273f937ea5e2", "id": 9}, {"samples": [{"hash": "bwyd98MLdC1", "uri": "/contracts/bwyd98MLdC1#cvrs", "label": "Purchase Agreement (Biomarin Pharmaceutical Inc)", "score": 25.9007530212, "published": true}, {"hash": "6vRPLFoY6XZ", "uri": "/contracts/6vRPLFoY6XZ#cvrs", "label": "Purchase Agreement (Prosensa Holding N.V.)", "score": 25.8952770233, "published": true}], "size": 3, "snippet_links": [{"key": "prior-to-the-closing", "type": "clause", "offset": [6, 26]}, {"key": "agreement-to-be", "type": "clause", "offset": [55, 70]}, {"key": "duly-authorized", "type": "clause", "offset": [71, 86]}, {"key": "executed-and-delivered", "type": "clause", "offset": [88, 110]}, {"key": "by-parent", "type": "clause", "offset": [111, 120]}, {"key": "the-rights-agent", "type": "clause", "offset": [125, 141]}, {"key": "agree-to", "type": "clause", "offset": [169, 177]}, {"key": "modifications-to-the", "type": "clause", "offset": [189, 209]}, {"key": "requested-by", "type": "clause", "offset": [227, 239]}, {"key": "prior-to-executing", "type": "clause", "offset": [257, 275]}, {"key": "the-holders", "type": "clause", "offset": [343, 354]}, {"key": "material-respect", "type": "definition", "offset": [407, 423]}], "snippet": "At or prior to the Closing, Parent shall cause the CVR Agreement to be duly authorized, executed and delivered by Parent and the Rights Agent; provided, that Parent may agree to reasonable modifications to the CVR Agreement as requested by the Rights Agent prior to executing the CVR Agreement so long as such modifications are not adverse to the Holders (as defined in the CVR Agreement) thereunder in any material respect.", "hash": "cf242929b239e607808042bd9cf1dd91", "id": 10}], "next_curs": "Ck0SR2oVc35sYXdpbnNpZGVyY29udHJhY3RzcikLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ig1jdnJzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"size": 202, "parents": [["contingent-value-rights", "Contingent Value Rights"], ["general-provisions", "General Provisions"], ["miscellaneous-provisions", "Miscellaneous Provisions"], ["miscellaneous", "Miscellaneous"], ["construction", "Construction"]], "title": "CVRs", "children": [], "id": "cvrs", "related": [["no-rights-as-warrant-securityholder-conferred-by-warrants-or-warrant-certificates", "No Rights as Warrant Securityholder Conferred by Warrants or Warrant Certificates", "No Rights as Warrant Securityholder Conferred by Warrants or Warrant Certificates"], ["common-shares", "Common Shares", "Common Shares"], ["fractional-shares", "Fractional Shares", "Fractional Shares"], ["company-shares", "Company Shares", "Company Shares"], ["additional-shares-or-substituted-securities", "Additional Shares or Substituted Securities", "Additional Shares or Substituted Securities"]], "related_snippets": [], "updated": "2026-05-03T04:25:59+00:00"}, "json": true, "cursor": ""}}